Effects of benralizumab injection: A Synthesis of Findings from 19 Studies

  1. Home
  2. Effects of benralizumab injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of benralizumab injection: A Synthesis of Findings from 19 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of benralizumab injection: A Synthesis of Findings from 19 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor alpha subunit and effectively depletes eosinophils, which are a type of white blood cell that plays a key role in asthma inflammation. Multiple studies have investigated the effectiveness of benralizumab in treating severe asthma. 15 showed that benralizumab reduced asthma exacerbations and improved lung function in patients with severe asthma, particularly when compared to placebo. This study also found that benralizumab was as effective as mepolizumab, another IL-5 inhibitor, in reducing asthma exacerbations. 5 highlighted the rapid effect of benralizumab in patients with severe allergic eosinophilic asthma, demonstrating significant reductions in blood eosinophil counts, improvements in asthma control, lung function, and a decrease in oral corticosteroid usage within just four weeks of the first injection. Other studies have also shown that benralizumab can be effective in reducing the need for oral corticosteroids, a common treatment for severe asthma, and has a favorable safety profile. 2 19

Benefits and Risks

Benefit summary

Benralizumab has been shown to be effective in reducing asthma exacerbations, improving lung function, and reducing the need for oral corticosteroids in patients with severe asthma. 15 19 4 5

Risk summary

Like all medications, benralizumab carries some potential risks. The most common side effects are mild and include injection site reactions and upper respiratory tract infections. 10 In rare cases, allergic reactions, including anaphylaxis, can occur. 10 7

Comparison between studies

Similarities between studies

Multiple studies have consistently shown the effectiveness of benralizumab in reducing asthma exacerbations and improving lung function in patients with severe asthma. 15 19 4 5

Differences between studies

The studies differ in the specific patient populations studied, the dosage and frequency of benralizumab administration, and the outcomes measured. For example, 15 focused on comparing benralizumab with other IL-5 inhibitors, while 5 investigated the rapid effects of benralizumab in a real-life setting.

Consistency and contradiction of results

The results of the studies are generally consistent in showing that benralizumab is an effective treatment for severe asthma. However, there are some differences in the specific patient populations where the effects are most pronounced. More research is needed to better understand the specific characteristics of patients who are most likely to benefit from benralizumab treatment. 9

Points to note for practical application

Benralizumab is a promising treatment option for patients with severe asthma. However, it is important to consider the potential risks and benefits of this medication, and to discuss any concerns with a healthcare provider. 10

Limitations of current research

The research on benralizumab is still ongoing, and more studies are needed to fully understand the long-term safety and efficacy of this medication. 10

Future research directions

Future research should focus on understanding the long-term safety and efficacy of benralizumab, identifying the optimal patient populations for this treatment, and evaluating the potential benefits of benralizumab in combination with other asthma treatments. 10

Conclusion

Benralizumab is a promising treatment for patients with severe asthma. It has been shown to be effective in reducing asthma exacerbations, improving lung function, and reducing the need for oral corticosteroids. 15 19 4 5 However, it is important to consider the potential risks and benefits of this medication, and to discuss any concerns with a healthcare provider. 10

Literature analysis of 19 papers
Positive Content
19
Neutral Content
0
Negative Content
0
Article Type
8
2
3
4
17
1.

Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.

Author: KuterDavid J, AllenLee F

Thrombocytopenia treatment

Avatrombopag is a new medication that can increase platelet counts in patients with chronic liver disease who need invasive procedures. In two Phase 1 studies, avatrombopag was safe and well-tolerated in healthy adults. Platelet counts increased significantly with doses of 20 mg daily after 13-16 days.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

Author: NairParameswaran, WenzelSally, RabeKlaus F, BourdinArnaud, LugogoNjira L, KunaPiotr, BarkerPeter, SprouleStephanie, PonnarambilSandhia, GoldmanMitchell,

Glucocorticoid sparing
Reduced asthma exacerbations

This study investigated whether benralizumab, a monoclonal antibody against the interleukin-5 receptor, could be used as an oral glucocorticoid-sparing therapy in patients with severe asthma associated with eosinophilia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.

Author: KatsaounouParaskevi, BuhlRoland, BrusselleGuy, PfisterPascal, MartínezRafael, WahnUlrich, BousquetJean

Asthma exacerbation
Undesirable effects

Systemic/oral corticosteroids (OCS) are used for decades in managing acute asthma exacerbations and uncontrolled severe asthma. However, OCS have undesirable effects and are not always effective in reducing the rate of exacerbations. Biologics, targeting IgE, IL-5, IL-5R or IL-4R α, have been proven safe and effective for patients with uncontrolled severe asthma, and are recommended as an alternative to chronic OCS therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

Author: FitzGeraldJ Mark, BleeckerEugene R, NairParameswaran, KornStephanie, OhtaKen, LommatzschMarek, FergusonGary T, BusseWilliam W, BarkerPeter, SprouleStephanie, GilmartinGeoffrey, WerkströmViktoria, AurivilliusMagnus, GoldmanMitchell,

Asthma treatment

This study assessed the efficacy and safety of benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as an add-on therapy for patients with severe, uncontrolled asthma and elevated blood eosinophil counts.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis.

Author: LiuWanshu, MaXuesu, ZhouWeikang

Asthma Treatment
Adverse Events

Benralizumab is a monoclonal antibody that depletes eosinophils and has shown efficacy in reducing asthma exacerbations. This study reviewed published randomized controlled trials to assess the incidence of adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

7.

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.

Author: Martínez-RiveraCarlos, Garcia-OlivéIgnasi, Urrutia-RoyoBlanca, Basagaña-TorrentoMaria, RosellAntoni, AbadJorge

Asthma treatment

This case report describes a patient with eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma who experienced rapid improvement in symptoms and lung function after treatment with benralizumab, an antieosinophilic monoclonal antibody.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.

Author: BleeckerEugene R, WechslerMichael E, FitzGeraldJ Mark, Menzies-GowAndrew, WuYanping, HirschIan, GoldmanMitchell, NewboldPaul, ZangrilliJames G

Asthma Treatment

Benralizumab, an anti-eosinophilic monoclonal antibody, is effective in reducing exacerbations and improving lung function in patients with severe, uncontrolled asthma with eosinophilic inflammation. This analysis shows that baseline factors, such as oral corticosteroid use, nasal polyposis, and lung function, can influence the efficacy of benralizumab.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.

Author: JacksonKim, BahnaSami L

Asthma and allergic disease treatment
Anaphylaxis
Hypersensitivity reactions

This review article discusses the adverse effects (AE) of five biologics approved for asthma and/or allergic diseases: omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Benralizumab for the Prevention of COPD Exacerbations.

Author: CrinerGerard J, CelliBartolome R, BrightlingChristopher E, AgustiAlvar, PapiAlberto, SinghDave, SinDon D, VogelmeierClaus F, SciurbaFrank C, BafadhelMona, BackerVibeke, KatoMotokazu, Ramírez-VenegasAlejandra, WeiYu-Feng, BjermerLeif, ShihVivian H, JisonMaria, O'QuinnSean, MakulovaNatalya, NewboldPaul, GoldmanMitchell, MartinUbaldo J,

Benralizumab was not associated with a lower annualized rate of COPD exacerbations than placebo in patients with moderate to very severe COPD.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Anti-IL5 therapies for asthma.

Author: FarneHugo A, WilsonAmanda, PowellColin, BaxLynne, MilanStephen J

Asthma exacerbation reduction
Improved HRQoL
Improved lung function

This review updates a previous review on the use of monoclonal antibodies targeting interleukin-5 (IL-5) or its receptor for asthma treatment. The review highlights the emerging evidence suggesting these antibodies reduce asthma exacerbations, improve health-related quality of life, and enhance lung function, leading to their inclusion in asthma guidelines.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

13.

Modern Interventions for Pediatric Atopic Dermatitis: An Updated Pharmacologic Approach.

Author: KondratukKatherine, NetravaliIlka Arun, Castelo-SoccioLeslie

Pediatric AD treatment
Targeted treatments

This review discusses emerging treatments for pediatric atopic dermatitis (AD), including topical and systemic therapies. The review highlights the significant advances brought by targeted treatments like dupilumab and JAK inhibitors and discusses the potential role of newer therapies in managing challenging AD patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Author: CastroMario, WenzelSally E, BleeckerEugene R, PizzichiniEmilio, KunaPiotr, BusseWilliam W, GossageDavid L, WardChristine K, WuYanping, WangBing, KhatryDeepak B, van der MerweRené, KolbeckRoland, MolfinoNestor A, RaibleDonald G

Asthma exacerbation prevention

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, depletes blood and airway eosinophils and is being studied as a treatment for uncontrolled eosinophilic asthma.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Matching-adjusted indirect comparison of benralizumab <i>versus</i> interleukin-5 inhibitors for the treatment of severe asthma: a systematic review.

Author: BourdinArnaud, HusereauDon, MolinariNicolas, GolamSarowar, SiddiquiMohd Kashif, LindnerLeandro, XuXiao

Asthma treatment

This study used matching-adjusted indirect comparison (MAIC) to assess the relative efficacy of benralizumab versus mepolizumab and reslizumab in patients with severe, uncontrolled asthma. After matching adjustment, benralizumab and mepolizumab showed similar efficacy in reducing exacerbations and improving lung function.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

16.

Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic Syndrome.

Author: KuangFei Li, LegrandFanny, MakiyaMichelle, WareJeanAnne, WetzlerLauren, BrownThomas, MageeTamika, PiligianBrent, YoonPryscilla, EllisJamie H, SunXiaoping, PanchSandhya R, PowersAstin, AlaoHawwa, KumarSheila, QuezadoMartha, YanLi, LeeNancy, KolbeckRoland, NewboldPaul, GoldmanMitchell, FayMichael P, KhouryPaneez, MaricIrina, KlionAmy D

Eosinophilia reduction
Elevated LDH
Headache

Benralizumab, a monoclonal antibody against interleukin-5 receptor alpha, was effective in reducing eosinophils and improving symptoms in patients with hypereosinophilic syndrome. More research is needed to determine long-term effectiveness and identify predictors of response.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma.

Author: YanLi, WangBing, ChiaYen Lin, RoskosLorin K

Reduced asthma symptoms

Benralizumab, an anti-eosinophil monoclonal antibody, demonstrated dose-proportional pharmacokinetics and was well-tolerated in patients with asthma. Body weight and ADA status affected drug exposure, while other factors had no significant impact.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Author: FergusonGary T, FitzGeraldJ Mark, BleeckerEugene R, LavioletteMichel, BernsteinDavid, LaForceCraig, MansfieldLyndon, BarkerPeter, WuYanping, JisonMaria, GoldmanMitchell,

Improved lung function
Reduced asthma exacerbations

Benralizumab, a monoclonal antibody targeting the interleukin 5 receptor α, has been shown to effectively reduce eosinophils, asthma exacerbations, and improve lung function in patients with severe eosinophilic asthma. This study examines the safety and efficacy of benralizumab in patients with mild to moderate persistent asthma.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.